ArticleAging2016
RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.
Open access · greenAbstract read
In one paragraph
Article in Aging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.Clinical lymphoma, myeloma & leukemia · 2018Trial
- Expression of NF-κB Isoforms and IKK Complex Subunits Differs in Peripheral Blood Mononuclear Cells (PBMCs) of Patients with Meningiomas: A Pilot Study.Life (Basel, Switzerland) · 2026Article
- Superior anti-DLBCL efficacy of novel organic arsenical Z2-A-Z2 through ROS-mediated apoptosis and critical NF-κB/IκBα signaling pathway inhibition.Journal of experimental & clinical cancer research : CR · 2026Article
- Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL).Cell death discovery · 2025Article
- Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.Cell death discovery · 2025Article
- Targeting RAB7 in human B lymphoma by a small molecule inhibitor arrests tumor cell growth.Frontiers in oncology · 2025Article
- TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Norisoboldine Reduces Arthritis Severity by Attenuating Inflammation, Oxidative Stress, and Extracellular Matrix Degradation in a Rat Model of Rheumatoid Arthritis.Journal of inflammation research · 2024Article
- Evaluation of Mitochondrial Respiratory Function in Murine Splenocytes.Methods in molecular biology (Clifton, N.J.) · 2024Article
- How lactate affects immune strategies in lymphoma.Frontiers in molecular biosciences · 2024Review
- The NF-κB multidimer system model: A knowledge base to explore diverse biological contexts.Science signaling · 2023Review
- Review
- Cyclin-dependent kinase 7/9 inhibitor SNS-032 induces apoptosis in diffuse large B-cell lymphoma cells.Cancer biology & therapy · 2022Article
- DSF/Cu induces antitumor effect against diffuse large B-cell lymphoma through suppressing NF-κB/BCL6 pathways.Cancer cell international · 2022Article
- Mitochondrial Dysfunction and Oxidative Stress in Rheumatoid Arthritis.Antioxidants (Basel, Switzerland) · 2022Review
- IQGAP2 acts as an independent prognostic factor and is related to immunosuppression in DLBCL.BMC cancer · 2021Article
- Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine.Oncotarget · 2020Review
- Article
- The Role and Underlying Mechanism of Exosomal CA1 in Chemotherapy Resistance in Diffuse Large B Cell Lymphoma.Molecular therapy. Nucleic acids · 2020Article
- 2α-Hydroxyeudesma-4,11(13)-Dien-8β,12-Olide Isolated fromBiomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 19 institutions in 9 countries.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital Zhengzhou University, Zhengzhou, Henan, China.
Zijun Y Xu-MonetteDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ling LiDepartment of Oncology, The First Affiliated Hospital Zhengzhou University, Zhengzhou, Henan, China.
Ganiraju C ManyamDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Carlo ViscoSan Bortolo Hospital, Vicenza, Italy.
Alexandar TzankovUniversity Hospital, Basel, Switzerland.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Santiago Montes-MorenoHospital Universitario Marques de Valdecilla, Santander, Spain.
Karen DybkaerAalborg University Hospital, Aalborg, Denmark.
April ChiuMemorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Attilio OraziWeill Medical College of Cornell University, New York, NY 10065, USA.
Youli ZuThe Methodist Hospital, Houston, TX 77030, USA.
Govind BhagatColumbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA.
Kristy L RichardsUniversity of North Carolina School of Medicine, Chapel Hill, NC 27514, USA.
Eric D HsiCleveland Clinic, Cleveland, OH 44195, USA.
William W L ChoiUniversity of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China.
J Han van KriekenRadboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Jooryung HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
Maurilio PonzoniSan Raffaele H. Scientific Institute, Milan, Italy.
Andrés J M FerreriSan Raffaele H. Scientific Institute, Milan, Italy.
Michael B MøllerOdense University Hospital, Odense, Denmark.
Ben M ParsonsGundersen Medical Foundation, La Crosse, WI 54601, USA.
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Miguel A PirisHospital Universitario Marques de Valdecilla, Santander, Spain.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lan V PhamDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ken H YoungDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USFirst Affiliated Hospital of Zhengzhou University · CNMarqués de Valdecilla University Hospital · ESSan Raffaele University of Rome · ITAalborg University Hospital · DKAsan Medical Center · KRCleveland Clinic · USCornell University · USGundersen Health System · USMemorial Sloan Kettering Cancer Center · USMethodist Hospital · USNewYork–Presbyterian Hospital · USNorthwestern University · USOdense University Hospital · DKOspedale San Bortolo · ITRadboud University Nijmegen · NLUniversity Hospital of Basel · CHUniversity of Hong Kong · HKUniversity of North Carolina at Chapel Hill · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MP4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1MConvergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9MMYC as a Biomarker in Aggressive Non-Hodgkin LymphomaR01CA187415 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, YONG · 2015 to 2019
$2.2MUT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5MDeep Sequencing of Small Regulatory RNAs in Diffuse Large B cell LymphomaRC1CA146299 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI XIAO, CHANGCHUN · 2009 to 2010
$1000kNCI NIH HHS P30 CA016672NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA136411NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA138688NCI NIH HHS R01 CA187415NCI NIH HHS RC1 CA146299
Abstract
It has been well established that nuclear factor kappa-B (NF-κB) activation is important for tumor cell growth and survival. RelA/p65 and p50 are the most common NF-kB subunits and involved in the classical NF-kB pathway. However, the prognostic and biological significance of RelA/p65 is equivocal in the field. In this study, we assessed RelA/p65 nuclear expression by immunohistochemistry in 487 patients with
Indexed as
AgedB-LymphocytesCell Line, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNF-kappa BSignal TransductionTranscription Factor RelANF-kappa BRELA protein, humanTranscription Factor RelAdiffuse large B-cell lymphomaGCBgene expression profilingNF-κBp65proteasome inhibitorTP53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.